These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31144418)

  • 21. New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration.
    Hamada Y; Ohtake J; Sohma Y; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem; 2002 Dec; 10(12):4155-67. PubMed ID: 12413869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions.
    Skwarczynski M; Sohma Y; Noguchi M; Kimura M; Hayashi Y; Hamada Y; Kimura T; Kiso Y
    J Med Chem; 2005 Apr; 48(7):2655-66. PubMed ID: 15801856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in prodrugs as drug delivery systems.
    Lin C; Sunkara G; Cannon JB; Ranade V
    Am J Ther; 2012 Jan; 19(1):33-43. PubMed ID: 21150770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells.
    Kelly GJ; Kia AF; Hassan F; O'Grady S; Morgan MP; Creaven BS; McClean S; Harmey JH; Devocelle M
    Org Biomol Chem; 2016 Oct; 14(39):9278-9286. PubMed ID: 27722734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphonate prodrugs: an overview and recent advances.
    Heidel KM; Dowd CS
    Future Med Chem; 2019 Jul; 11(13):1625-1643. PubMed ID: 31469328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the acyl groups on O-->N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor.
    Hamada Y; Matsumoto H; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2727-30. PubMed ID: 12873502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.
    Wang B; Nimkar K; Wang W; Zhang H; Shan D; Gudmundsson O; Gangwar S; Siahaan T; Borchardt RT
    J Pept Res; 1999 Apr; 53(4):370-82. PubMed ID: 10406215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prodrugs: Some thoughts and current issues.
    Stella VJ
    J Pharm Sci; 2010 Dec; 99(12):4755-65. PubMed ID: 20821387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. General strategy for the preparation of membrane permeable fluorogenic peptide ester conjugates for in vivo studies of ester prodrug stability.
    Li X; Taylor JS
    Bioorg Med Chem; 2004 Feb; 12(3):545-52. PubMed ID: 14738963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prodrug resistance mechanism is involved in colibactin biosynthesis and cytotoxicity.
    Brotherton CA; Balskus EP
    J Am Chem Soc; 2013 Mar; 135(9):3359-62. PubMed ID: 23406518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of first photoresponsive prodrug of paclitaxel.
    Skwarczynski M; Noguchi M; Hirota S; Sohma Y; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4492-6. PubMed ID: 16806915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is prodrug design an approach to increase water solubility?
    Sanches BMA; Ferreira EI
    Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy.
    Mandal A; Patel M; Sheng Y; Mitra AK
    Curr Drug Targets; 2016; 17(15):1773-1798. PubMed ID: 26648076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrugs of peptides. IV: Bioreversible derivatization of the pyroglutamyl group by N-acylation and N-aminomethylation to effect protection against pyroglutamyl aminopeptidase.
    Bundgaard H; Møss J
    J Pharm Sci; 1989 Feb; 78(2):122-6. PubMed ID: 2565975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel prodrug strategy for beta-dicarbonyl carbon acids: syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives.
    Dhareshwar SS; Stella VJ
    J Pharm Sci; 2010 Jun; 99(6):2711-23. PubMed ID: 20020525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporin A prodrugs: design, synthesis and biophysical properties.
    Hamel AR; Hubler F; Carrupt A; Wenger RM; Mutter M
    J Pept Res; 2004 Feb; 63(2):147-54. PubMed ID: 15009536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prodrugs in medicinal chemistry and enzyme prodrug therapies.
    Walther R; Rautio J; Zelikin AN
    Adv Drug Deliv Rev; 2017 Sep; 118():65-77. PubMed ID: 28676386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of prodrugs - design by quantum mechanics methods.
    Karaman R; Fattash B; Qtait A
    Expert Opin Drug Deliv; 2013 May; 10(5):713-29. PubMed ID: 23540707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prodrugs design based on inter- and intramolecular chemical processes.
    Karaman R
    Chem Biol Drug Des; 2013 Dec; 82(6):643-68. PubMed ID: 23998799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2018 Dec; 292():58-66. PubMed ID: 29729352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.